Hydroxy, Bonded Directly To Carbon, Or Ether Containing (h Of -oh May Be Replaced By A Substituted Or Unsubstituted Ammonium Ion Or A Group Ia Or Iia Light Metal) Patents (Class 564/158)
-
Plasminogen Activator Inhibitor-1 Inhibitors and Methods of Use Thereof to Modulate Lipid Metabolism
Publication number: 20100137194Abstract: The invention relates to plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or condition associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to modulate lipid metabolism and treat conditions associated with elevated PAI-1, cholesterol, or lipid levels.Type: ApplicationFiled: November 23, 2009Publication date: June 3, 2010Applicants: EASTERN MICHIGAN UNIVERSITYInventors: Daniel A. Lawrence, Cory Emal, Jacqueline Cale, Enming J. Su, Mark Warnock, Shih-Hon Li, Jeanne A. Cupp -
Publication number: 20100120872Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.Type: ApplicationFiled: September 11, 2009Publication date: May 13, 2010Applicant: Novartis AGInventors: Markus Rolf Dobler, Francois Lenoir, David Thomas Parker, Yunshan Peng, Grazia Piizzi, Sompong Wattanasin
-
Patent number: 7714170Abstract: Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially A? amyloidosis, such as observed in Alzheimer's disease, use in the reduction of A? peptide in vivo, use in modulating APP processing, and use in modulating the activity of APP secretase.Type: GrantFiled: December 8, 2008Date of Patent: May 11, 2010Assignee: Proteotech, Inc.Inventors: Alan D. Snow, Qubai Hu, Judy A. Cam
-
Publication number: 20100113504Abstract: The present invention relates to a compound of Formula (I), its geometrical isomers, in an optically active form as enantiomers, diastereomers, as well as in the form of racemate, as well as pharmaceutically acceptable salts thereof, wherein R is selected from CONHOH, CONHCH2SH, CONHCH2SCOCH3, SH, SCOCH3, SCH3, N(OH)COH, COCONHCH3 and CF3 for the preparation of a medicament, in particular for selectively inducing terminal differentiation of neoplastic cells and thereby inhibiting proliferation of such cells, for inducing differentiation of tumor cells in a tumor, for inhibiting the activity of histone deacetylase and for the treatment of primary cancer or secondary cancer.Type: ApplicationFiled: March 12, 2008Publication date: May 6, 2010Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.Inventors: Stephan Hanessian, Luciana Auzzas, Giuseppe Giannini, Claudio Pisano, Loredana Vesci, Walter Cabri
-
Publication number: 20100069630Abstract: The present invention discloses novel naphthalenyloxypropenyl derivatives useful for inhibiting the enzyme activity of histone deacetylase, leading effective suppression of cancer cell proliferation.Type: ApplicationFiled: November 1, 2007Publication date: March 18, 2010Applicants: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, CRYSTALGENOMICS, INCInventors: Cheol Hae Lee, Hee Jung Jung, Jae Hak Kim, Won Jang Jeong, Joong Myung Cho, Seong Gu Ro, Young Lan Hyun, Cheol Soon Lee
-
Publication number: 20100062465Abstract: Provided are compositions and methods for intracellular detection of enzyme activity. One example of a composition is a histone deacetylase substrate comprising a compound of the following formula (I): One example of a method is a method for detecting histone deacetylase activity comprising introducing a compound according to formula (1) to a plurality of cells and monitoring the cells with magnetic resonance spectroscopy.Type: ApplicationFiled: April 20, 2007Publication date: March 11, 2010Inventors: Sabrina M. Ronen, Juri G. Gelovani, William G. Bornmann, Jihai Pang, Ashutosh Pal, William P. Tong, Ashutosh Paz, William P. Tong, David S. Maxwell, Madhuri Sankaranarayanapillai
-
Publication number: 20100048716Abstract: This invention relates to crystal forms of aliskiren hemifumarate and various embodiments related thereto, e.g. pharmaceutical preparations, processes for the manufacture of the crystal forms, pharmaceuticals uses and the like. The crystal forms have particularly advantageous properties e.g. they are useful in the manufacture of blood-pressure lowering pharmaceutical preparations and the like.Type: ApplicationFiled: November 5, 2007Publication date: February 25, 2010Inventors: Frank Stowasser, Stephanie Monnier
-
Patent number: 7663000Abstract: The present invention provides optionally substituted compounds of the formula I or salts thereof; wherein R1 is O or S when double bonded to the ring or is OH, SH, or a protected equivalent, when single bonded to the ring, R2 is hydrogen or more preferably an C1-C10 organic group attached by a carbon atom, X is H, O, OO, S or SS R3 is absent where X?H, is hydrogen or is a hydroxyl or thiol protecting group, R4 is a hetero- or preferably homo-cyclic aryl group, optionally substituted with a further group R5 and groups T1 are each, independently, absent, hydrogen or an S—R6 group, where any/each R6 is independently an organic group of molecular weight up to around 500 amu. The invention further provides a method for the synthesis of such compounds and a method of treatment comprising administering such compounds to a mammalian subject.Type: GrantFiled: July 23, 2004Date of Patent: February 16, 2010Assignee: A-Viral ASAInventors: David Walterus Cornelius Dekkers, Lucien Adrianus Aarden, Janna Alberdina Ten Brinke
-
Publication number: 20100036162Abstract: Process for the industrial synthesis of the compound of formula (I)Type: ApplicationFiled: August 4, 2009Publication date: February 11, 2010Applicant: LES LABORATOIRES SERVIERInventors: Christophe Hardouin, Jean-Pierre Lecouve, Nicolas Bragnier
-
Patent number: 7629367Abstract: Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner.Type: GrantFiled: June 3, 2005Date of Patent: December 8, 2009Assignee: Merck & Co., Inc.Inventors: Barbara Hanney, Yuntae Kim, Michael R. Krout, Robert S. Meissner, Helen J. Mitchell, Jeffrey Musselman, James J. Perkins, Jiabing Wang
-
Publication number: 20090298947Abstract: The present invention relates to polymorphic and amorphous forms of Lacosamide, processes of preparing the polymorphic and amorphous forms, pharmaceutical compositions containing the same, therapeutic uses thereof and methods of treatment employing the same.Type: ApplicationFiled: May 27, 2009Publication date: December 3, 2009Applicant: PLIVA HRVATSKA D.O.O.Inventors: Tina MUNDORFER, Marina MARKOVIC, Nada KOSUTIC HULITA, Miroslav ZEGARAC
-
Publication number: 20090292001Abstract: The present invention relates to certain tricyclic derivatives which are capable of inhibiting histone deacetylases. The compounds of this invention are therefore useful in treating diseases associated with abnormal histone deacetylase activities. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds, and methods of preparing these compounds are also disclosed.Type: ApplicationFiled: May 8, 2009Publication date: November 26, 2009Applicant: Chipscreen Biosciences, Ltd.Inventors: Xian-Ping LU, Zhi-Bin Li, Zhi-Qiang Ning
-
Publication number: 20090292024Abstract: It is an object of the present invention to provide a substituted propanamide derivative or a pharmacologically acceptable salt thereof that is useful as a prophylactic or therapeutic agent for a bone metabolic disease. The present invention relates to a pharmaceutical composition comprising a compound having General Formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein, R1 represents a C6-C10 aryl group that may be substituted by a group selected from Substituent Group ?, for example; R2 represents a C6-C10 aryl group that may be substituted by a group selected from Substituent Group ?, for example; and X represents a hydroxyl group or a C1-C6 alkoxy group, for example].Type: ApplicationFiled: July 18, 2006Publication date: November 26, 2009Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Kazumasa Aoki, Koji Suda, Kentoku Gotanda, Tomio Kimura
-
Patent number: 7612236Abstract: It is provided that a method for producing an optically active bisamidoalcohol compound represented by the formula (3): wherein R1 represents a C1-6 alkyl group, an optionally substituted phenyl group, an optionally substituted aralkyl group or a hydrogen atom, or two R1s, which are bonded to the same carbon atom, are bonded to form a ring together with the carbon atom to which they are bonded, R2 represents a C1-6 alkyl group, an optionally substituted phenyl group, a 1-naphthyl group, a 2-naphthyl group or an optionally substituted aralkyl group, R3 and R4 are the same or different, and each represents a hydrogen atom or C1-3 alkyl group, m represents an integer of 0 to 2, and * represents an asymmetric center, which comprises reacting an optically active aminoalcohol compound represented by the formula (1): wherein R1, R2 and * are as defined above, with a diester compound represented by the formula (2): wherein R3, R4 and m are as defined above and R5 represents a C1-3 alkyl group,Type: GrantFiled: December 21, 2004Date of Patent: November 3, 2009Assignee: Sumitomo Chemical Company, LimitedInventor: Makoto Itagaki
-
Patent number: 7601872Abstract: Disclosed are compounds capable of facilitating transport of biologically active agents or substances into cells having the general structure: wherein Q is selected from the group consisting of N, O and S; L is any bivalent organic radical capable of linking each Q, such as C, CH, (CH2)l, or {(CH2)i-Y—(CH2)j}k, wherein Y is selected from the group consisting of CH2, an ether, a polyether, an amide, a polyamide, an ester, a sulfide, a urea, a thiourea, a guanidyl, a carbamoyl, a carbonate, a phosphate, a sulfate, a sulfoxide, an imine, a carbonyl, and a secondary amino group and wherein Y is optionally substituted by —X1-L?-X2-Z or -Z; R1-R6, independently of one another, are selected from the group consisting of H, —(CH2)p-D-Z, an alkyl, an alkenyl, an aryl, and an alkyl or alkyl ether optionally substituted by one or more of an alcohol, an aminoalcohol, an amine, an amide, an ether, a polyether, a polyamide, an ester, a mercaptan, an alkylthio, a urea, a thiourea, a guanidyl, or a carbamoyl group, and wType: GrantFiled: January 21, 2005Date of Patent: October 13, 2009Assignee: Life Technologies CorporationInventors: Yongliang Chu, Malek Masoud, Gulilat Gebeyehu
-
Patent number: 7601876Abstract: Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially A? amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, AA/SAA amyloidosis, such as observed in systemic AA amyloidosis and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.Type: GrantFiled: March 5, 2007Date of Patent: October 13, 2009Assignee: Proteotech, Inc.Inventors: Alan D. Snow, Beth P. Nguyen, Gerardo M. Castillo, Virginia J. Sanders, Thomas P. Lake, Lesley Larsen, Rex T. Weavers, Stephen D. Lorimer, David S. Larsen, David L. Coffen, Charlotte Coffen, legal representative
-
Patent number: 7598412Abstract: The present invention provides compounds of Formula I useful as modulators of ABC transporter activity, or a pharmaceutically acceptable salt thereof, wherein RB, n, B, RC, RD, RE, A, and Z are described generally and in classes and subclasses below. The present invention also provides pharmaceutical compositions, methods and kits associated with Formula I, useful for as modulators, and for the treatments of disease and disease conditions associated with ABC transporter proteins.Type: GrantFiled: October 8, 2004Date of Patent: October 6, 2009Assignee: Vertex Pharmaceuticals IncorporatedInventors: Sara S. Hadida Ruah, Ashvani K. Singh, Mark T. Miller, Matthew Hamilton, Peter D. J. Grootenhuis
-
Publication number: 20090233949Abstract: The invention relates to the compounds of formula (I) having antithrombotic activity which especially inhibit blood clotting factor IXa, to methods for producing the same and to the use thereof as drugs.Type: ApplicationFiled: March 9, 2009Publication date: September 17, 2009Applicant: SANOFI-AVENTISInventors: Henning STEINHAGEN, Markus FOLLMANN, Jochen GOERLITZER, Herman SCHREUDER
-
Publication number: 20090197965Abstract: Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially A? amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.Type: ApplicationFiled: November 11, 2008Publication date: August 6, 2009Inventors: Alan D. Snow, Beth P. Nguyen, Gerardo M. Castillo, Virginia J. Sanders, Thomas P. Lake, Lesley Larsen, Rex T. Weavers, David S. Lorimer, David S. Larsen, David L. Coffen, Charlotte Coffen, Stephen D. Lorimer
-
Publication number: 20090156805Abstract: Novel cycloalkane carboxamide derivatives having an action that selectively inhibits cathepsin K, and a production process thereof, are provided. A cycloalkane carboxamide derivative represented by the following general formula (I), or a pharmaceutically acceptable salt thereof: (wherein R1 and R2 represent (substituted) alkyl groups, (substituted) alkenyl groups, (substituted) alkynyl groups, (substituted) aromatic hydrocarbon groups or (substituted) heterocyclic groups, ring A represents an alkylidene group having 5 to 7 carbon atoms, and ring B represents a formyl group or a hydroxymethyl group).Type: ApplicationFiled: January 10, 2007Publication date: June 18, 2009Applicant: SEIKAGAKU CORPORATIONInventors: Nobuo Kobayashi, Tsuneo Koji, Hisatomo Kunii, Mizuho Kataoka
-
Patent number: 7547731Abstract: The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.Type: GrantFiled: July 3, 2007Date of Patent: June 16, 2009Assignee: Pfizer IncInventors: Alan Daniel Brown, Mark Edward Bunnage, Charlotte Alice Louise Lane, Russell Andrew Lewthwaite, Paul Alan Glossop, Kim James, David Anthony Price
-
Publication number: 20090143472Abstract: The present invention is concerned with novel compounds and their use for the preparation of lacosamide. The present invention also contemplates processes for the preparation of lacosamide employing the novel compound of general Formula II, Formula IIa or Formula IIb as intermediate. Wherein R1 is —OH or —OMe; R2 is —OH or —NH—CH2—C6H5.Type: ApplicationFiled: December 3, 2008Publication date: June 4, 2009Inventors: Mukesh Kumar Madhra, Pankaj Kumar Singh, Chandra Has Khanduri
-
Publication number: 20090111874Abstract: The present invention relates to novel phenyl-N-acyl derivatives of biogenic amines and amino acids of general formula (I) as cyclooxynease inhibitors, possessing analgetic and anti-inflammatory properties and devoid of side effects in particular ulcerogeneity and pro-spasmodic actions, as well as capability to potentiate effect of other analgetics, and possessing in addition antihypoxic, antidepressant and anti-Parkinsonistic action; as well as to the processes for the preparation novel and known phenyl-N-acyl derivatives of biogenic amines, to a pharmaceutical composition and to an agent comprising compounds of general formula (I) as well as to use thereof and a method of treating.Type: ApplicationFiled: March 24, 2006Publication date: April 30, 2009Applicant: OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU PHARMENTERPRISESInventors: Vladimir Evgenievich Nebolsin, Tatyana Alexandrovna Kromova, Galina Alexandrovna Zheltukhina, Violetta Leonidovna Kovaleva
-
Patent number: 7482487Abstract: The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.Type: GrantFiled: March 10, 2005Date of Patent: January 27, 2009Assignee: Pfizer IncInventors: Alan Daniel Brown, Justin Stephen Bryans, Paul Alan Glossop, Charlotte Alice Louise Lane, Simmon John Mantell
-
Publication number: 20090023710Abstract: There is provided a compound having Formula (I) wherein each of R1, R2, R3, R4, R5, R6 and R7 are independently selected from (a) H, (b) R17, —OC(R17)3, —OCH(R17)2, —OCH2R17, —C(R17)3, —CH(R17)2, or —CH2R17 wherein R17 is a halogen; (c) —CN; (d) optionally substituted alkyl, (e) optionally substituted heteroalkyl; (f) optionally substituted aryl; (g) optionally substituted heteroaryl; (h) optionally substituted arylalkyl; (i) optionally substituted heteroarylalkyl; (j) hydroxy; (k) alkoxy; (l) aryloxy; (m) —SO2-alkyl; and (n) —N(R11)C(O)R13; wherein the optional substituents of (d) (e) (f) (h) and (i) are selected from the group consisting of: C1-6 alkyl, halo, cyano, nitro, haloalkyl, hydroxy, alkoxy, carboxy, carboxyalkyl, carboxamide, mercapto, amino, alkylamino, dialkylamino, sulfonyl, sulfonamido, aryl and heteroaryl; each of rings A and B are selected from five or six membered carbon rings optionally containing one or more hetero atoms selected from N, S, and O and optionally having fused thereto a furtType: ApplicationFiled: January 2, 2008Publication date: January 22, 2009Inventors: Nigel Vicker, Joanna Mary Day, Helen Victoria Bailey, Wesley Heaton, Ana Maria Ramos Gonzalez, Christopher Mark Sharland, Michael John Reed, Atul Purohit, Barry Victor Lloyd Potter
-
Patent number: 7479571Abstract: One aspect of the present invention relates to compounds, comprising at least two moieties selected from the group consisting of aryl sulfonates and aryl sulfates. A second aspect of the present invention relates to combinatorial libraries of the aforementioned compounds. The present invention also relates to compositions comprising a compound of the present invention. A fourth aspect of the present invention relates to the use of a compound or composition of the present invention in a method for inhibiting bioadhesion to a surface. Another aspect of the present invention relates to the use of a compound or composition of the present invention in a method for enhancing bioadhesion to a surface.Type: GrantFiled: February 7, 2005Date of Patent: January 20, 2009Assignee: Cernofina, LLCInventors: Randall S. Alberte, Robert D. Smith
-
Publication number: 20090012010Abstract: Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type and/or T-type calcium channel activity are disclosed. Specifically, a series of compounds containing both an amino acid functionality and multiple aromatic rings are disclosed of the general formula (1) where X is benzhydryl, or an aromatic or heteroaromatic ring.Type: ApplicationFiled: May 14, 2008Publication date: January 8, 2009Applicant: Neuromed Phramaceuticals Ltd.Inventors: Robert Galemmo, JR., Richard Holland, Yanbing Ding, Lingyun Zhang, Gabriel Hum, Navjot Chahal, Joseph Duffy, Christian Stevenson, Andrew Ullman
-
Patent number: 7470817Abstract: Disclosed are compounds capable of facilitating transport of biologically active agents or substances into cells having the general structure: wherein Q is selected from the group consisting of N, O and S; L is any bivalent organic radical capable of linking each Q, such as C, CH, (CH2)I, or {(CH2)i-Y—(CH2)j}k, wherein Y is selected from the group consisting of CH2, an ether, a polyether, an amide, a polyamide, an ester, a sulfide, a urea, a thiourea, a guanidyl, a carbamoyl, a carbonate, a phosphate, a sulfate, a sulfoxide, an imine, a carbonyl, and a secondary amino group and wherein Y is optionally substituted by —X1-L?-X2-Z or -Z; R1-R6, independently of one another, are selected from the group consisting of H, —(CH2)p-D-Z, an alkyl, an alkenyl, an aryl, and an alkyl or alkyl ether optionally substituted by one or more of an alcohol, an aminoalcohol, an amine, an amide, an ether, a polyether, a polyamide, an ester, a mercaptan, an alkylthio, a urea, a thiourea, a guanidyl, or a carbamoyl group, and wType: GrantFiled: December 28, 2006Date of Patent: December 30, 2008Assignee: Invitrogen CorporationInventors: Yongliang Chu, Malek Masoud, Gulilat Gebeyehu
-
Publication number: 20080312286Abstract: The present invention is directed to compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.Type: ApplicationFiled: July 26, 2005Publication date: December 18, 2008Inventors: Anthony B. Pinkerton, Jean-Michel Vernier, Rowena Cube, John Hutchinson, Celine Bonnefous, Theodore Kamenecka
-
Patent number: 7459585Abstract: The present invention provides an AP-1 activation inhibitor, NF-kappa B activation inhibitor, inflammatory cytokine production inhibitor, matrix metalloprotease production inhibitor, inflammatory cell adhesion molecule expression inhibitor, anti-inflammatory agent, antirheumatic agent, immunosuppressant, cancer metastasis inhibitor, remedy for arteriosclerosis and antiviral agent which contain the benzene derivative of the following general formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.Type: GrantFiled: March 24, 2005Date of Patent: December 2, 2008Assignee: Ajinomoto Co., Inc.Inventors: Yukio Iino, Kohichi Fujita, Takashi Tsuji, Ariko Kodaira, Kenji Takehana, Tsuyoshi Kobayashi, Takashi Yamamoto
-
Publication number: 20080280835Abstract: The present invention is directed to the use of a class of peptide compounds for treating non-inflammatory musculoskeletal pain or/and non-inflammatory osteoarthritic pain.Type: ApplicationFiled: August 18, 2006Publication date: November 13, 2008Inventors: Bettina Beyreuther, Thomas Stohr
-
Patent number: 7449493Abstract: The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.Type: GrantFiled: July 14, 2005Date of Patent: November 11, 2008Assignees: Bristol-Myers Squibb Pharmaceutical Company, Bristol-Myers Squibb Pharma CompanyInventors: Percy Carter, Robert Cherney
-
Corrosion and gas hydrate inhibitors having improved water solubility and increased biodegradability
Patent number: 7435845Abstract: Corrosion and gas hydrate inhibitors having improved water solubility and increased biodegradability The invention thus provides the use of compounds of the formula (1) where R1, R2 are each independently C1- to C22-alkyl, C2- to C22-alkenyl, C6- to C30-aryl or C7- to C30-alkylaryl, R3 is C1- to C22-alkyl, C2- to C22-alkenyl, C6- to C30-aryl or C7- to C30-alkylaryl, —CHR5—COO? or —O?, R4 is M, hydrogen or an organic radical which optionally contains heteroatoms and has from 1 to 100 carbon atoms, B is an optionally substituted C1- to C10-alkylene group, D is an ethylene group substituted by an organic radical having from 1 to 600 carbon atoms, X, Y are each independently O or NR6, R5, R6 are each independently hydrogen, C1- to C22-alkyl, C2- to C22-alkenyl, C6- to C30-aryl or C7- to C30-alkylaryl, and M is a cation as corrosion and gas hydrate inhibitors, and also the compounds of formula 1.Type: GrantFiled: February 20, 2004Date of Patent: October 14, 2008Assignee: Clariant Produkte (Deutschland) GmbHInventors: Uwe Dahlmann, Michael Feustel -
Publication number: 20080249335Abstract: The present invention is directed to a compound represented by Structural Formula I: wherein the variables are described herein. Also included are methods of making the compounds of Structural Formula (I) and methods of using the compounds as antioxidants.Type: ApplicationFiled: October 17, 2007Publication date: October 9, 2008Inventors: Ashok L. Cholli, Rajesh Kumar, Taizoon Canteenwala, Vijayendra Kumar
-
Publication number: 20080242730Abstract: The present invention provides hydroxamic acid derivatives represented by the formula, having antioxidation, collagen biosynthesis promotion and skin pore contraction effects, and a method for preparation thereof. Further, the present invention provides skin-care external compositions for preventing skin aging, containing said hydroxamic acid derivatives represented by the formula as an active ingredient.Type: ApplicationFiled: March 21, 2006Publication date: October 2, 2008Inventors: Ho Sik Rho, Heung Soo Baek, Jeong A. Lee, Chang Man Park, Duck Hoo Kim, Ih Soop Chang, Ok Sub Lee
-
Publication number: 20080200542Abstract: The present invention relates to benzoyl-substituted serineamides of the formula I in which the variables R1 to R11 are as defined in the description, and to their agriculturally useful salts, to processes and intermediates for their preparation, and to the use of these compounds or of compositions comprising these compounds for controlling unwanted plants.Type: ApplicationFiled: March 29, 2006Publication date: August 21, 2008Applicant: BASF AktiengesellschaftInventors: Matthias Witschel, Cyrill Zagar, Eike Hupe, Toralf Kuhn, William Karl Moberg, Liliana Parra Rapado, Frank Stelzer, Andrea Vescovi, Robert Reinhard, Bernd Sievernich, Klaus Grossmann, Thomas Ehrhardt
-
Publication number: 20080167380Abstract: Novel acyl hydrazides of the formula (I), in which R1-R9 have the meanings indicated in claim 1, are SGK inhibitors and can be used for the treatment of SGK-induced diseases and complaints, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, generally in fibroses and inflammatory processes of any type.Type: ApplicationFiled: March 10, 2006Publication date: July 10, 2008Inventors: Rolf Gericke, Dieter Dorsch, Werner Mederski, Markus Klein, Norbert Beier, Florian Lang
-
Patent number: 7358383Abstract: The present invention relates to synthetic green tea derived polyphenolic compounds, their modes of syntheses, and their use in inhibiting proteasomal activity and in treating cancers. The present invention is also directed to pharmaceutical compositions useful in methods of inhibiting proteasomes and of treating cancers.Type: GrantFiled: January 26, 2004Date of Patent: April 15, 2008Assignees: University of South Florida, McGill University, The Hong Kong Polytechnic UniversityInventors: Q. Ping Dou, Tak-Hang Chan, David M. Smith
-
Patent number: 7351862Abstract: Alpha, omega-difunctional aldaramides, in particular diaminoaldaramides, dihydroxyaldaramides, bis(alkoxycarbonylalkyl)aldaramides, and bis(carboxyalkyl)aldaramides, and processes for preparing the aldaramides are provided.Type: GrantFiled: February 23, 2006Date of Patent: April 1, 2008Assignee: E.I. du Pont de Nemours and CompanyInventors: Mark Allen Andrews, Henry Keith Chenault, Garret D. Figuly
-
Patent number: 7348451Abstract: The invention provides the use of compounds of the formula (1) where R1, R2 are each independently C1- to C22-alkyl, C2- to C22-alkenyl, C6- to C30-aryl or C7- to C30-alkylaryl, R3 is C1- to C22-alkyl, C2- to C22-alkenyl, C6- to C30-aryl or C7- to C30-alkylaryl, —CHR5—COO? or —O?, R4 is M, hydrogen or an organic radical which optionally contains heteroatoms and has from 1 to 100 carbon atoms, B is an optionally substituted C1- to C30-alkylene group, D is an organic radical which optionally contains heteroatoms and has from 1 to 600 carbon atoms, X, Y are each independently O or NR6, R5, R6 are each independently hydrogen, C1- to C22-alkyl, C2- to C22-alkenyl, C6- to C30-aryl or C7- to C30-alkylaryl, and M is a cation as gas hydrate inhibitors.Type: GrantFiled: March 28, 2007Date of Patent: March 25, 2008Assignee: Clariant Produkte (Deutschland) GmbHInventors: Uwe Dahlmann, Michael Feustel
-
Patent number: 7323594Abstract: Disclosed are compounds capable of facilitating transport of biologically active agents or substances into cells having the general structure: wherein Q is selected from the group consisting of N, O and S; L is any bivalent organic radical capable of linking each Q, such as C, CH, (CH2)l, or {(CH2)i-Y—(CH2)j}k, wherein Y is selected from the group consisting of CH2, an ether, a polyether, an amide, a polyamide, an ester, a sulfide, a urea, a thiourea, a guanidyl, a carbamoyl, a carbonate, a phosphate, a sulfate, a sulfoxide, an imine, a carbonyl, and a secondary amino group and wherein Y is optionally substituted by -X1-L?-X2-Z or -Z; R1-R6, independently of one another, are selected from the group consisting of H, —(CH2)p-D-Z, an alkyl, an alkenyl, an aryl, and an alkyl or alkyl ether optionally substituted by one or more of an alcohol, an aminoalcohol, an amine, an amide, an ether, a polyether, a polyamide, an ester, a mercaptan, an alkylthio, a urea, a thiourea, a guanidyl, or a carbamoyl group, andType: GrantFiled: December 28, 2006Date of Patent: January 29, 2008Assignee: Invitrogen CorporationInventors: Yongliang Chu, Malek Masoud, Gulilat Gebeyehu
-
Patent number: 7241810Abstract: The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.Type: GrantFiled: March 21, 2005Date of Patent: July 10, 2007Assignee: Pfizer IncInventors: Alan Daniel Brown, Mark Edward Bunnage, Charlotte Alice Louise Lane, Russell Andrew Lewthwaite, Paul Alan Glossop, Kim James, David Anthony Price
-
Patent number: 7238834Abstract: The present invention relates to substantially pure piperidine derivative compounds of the formulae: wherein R1 is hydrogen or hydroxy; R2 is hydrogen; or R1 and R2 taken together form a second bond between the carbon atoms bearing R1 and R2; R3 is —COOH or —COOR4; R4 has 1 to 6 carbon atoms; A, B, and D are the substituents of their respective rings each of which may be different or the same and are hydrogen, halogens, alkyl, hydroxy, alkoxy, or other substituents. A process of preparing such piperidine derivative compounds in substantially pure form is also disclosed.Type: GrantFiled: October 14, 2005Date of Patent: July 3, 2007Assignee: AMR Technology, Inc.Inventor: Thomas E. D'Ambra
-
Patent number: 7230133Abstract: The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.Type: GrantFiled: April 29, 2004Date of Patent: June 12, 2007Assignee: Bristol-Myers Squibb CompanyInventor: Percy Carter
-
Patent number: 7214814Abstract: The invention provides the use of compounds of the formula (1) where R1, R2 are each independently C1- to C22-alkyl, C2- to C22-alkenyl, C6- to C30-aryl or C7- to C30-alkylaryl, R3 is C1- to C22-alkyl, C2- to C22-alkenyl, C6- to C30-aryl or C7- to C30-alkylaryl, —CHR5—COO? or —O?, R4 is M, hydrogen or an organic radical which optionally contains heteroatoms and has from 1 to 100 carbon atoms, B is an optionally substituted C1- to C30-alkylene group, D is an organic radical which optionally contains heteroatoms and has from 1 to 600 carbon atoms, X, Y are each independently O or NR6, R5, R6 are each independently hydrogen, C1- to C22-alkyl, C2- to C22-alkenyl, C6- to C30-aryl or C7- to C30-alkylaryl, and M is a cation as gas hydrate inhibitors.Type: GrantFiled: February 20, 2004Date of Patent: May 8, 2007Assignee: Clariant Produkte (Deutschland) GmbHInventors: Uwe Dahlmann, Michael Feustel
-
Patent number: 7205437Abstract: The present invention relates to androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity, which are nonsteroidal ligands for the androgen receptor.Type: GrantFiled: May 10, 2005Date of Patent: April 17, 2007Assignee: University of Tennessee Research FoundationInventors: James T. Dalton, Duane D. Miller, Yali He, Donghua Yin
-
Patent number: 7183431Abstract: A dihydroxy aromatic compound having a Formula (I), wherein R1 is a C6–C60 aromatic divalent functionality, R2 at each occurrence, can be the same or different and is independently at each occurrence selected from the group consisting of a cyano functionality, a nitro functionality, a halogen, an aliphatic functionality having 1 to 10 carbons, a cycloaliphatic functionality having 3 to 10 carbons and an aromatic functionality having 6 to 10 carbons, and “n” is an integer having a value of 0 to 4.Type: GrantFiled: November 29, 2005Date of Patent: February 27, 2007Assignee: General Electric CompanyInventors: Nagarajan Arumugam, Radhakrishna As, Jan Pleun Lens, Tilak Raj, Binod Sahoo
-
Patent number: 7166745Abstract: Disclosed are compounds capable of facilitating transport of biologically active agents or substances into cells having the general structure: wherein Q is selected from the group consisting of N, O and S; L is any bivalent organic radical capable of linking each Q, such as C, CH, (CH2)1, or {(CH2)i—Y—(CH2)j}k, wherein Y is selected from the group consisting of CH2, an ether, a polyether, an amide, a polyamide, an ester, a sulfide, a urea, a thiourea, a guanidyl, a carbamoyl, a carbonate, a phosphate, a sulfate, a sulfoxide, an imine, a carbonyl, and a secondary amino group and wherein Y is optionally substituted by —X1—L?—X2—Z or —Z; R1–R6, independently of one another, are selected from the group consisting of H, —CH2)p—D—Z, an alkyl, an alkenyl, an aryl, and an alkyl or alkyl ether optionally substituted by one or more of an alcohol, an aminoalcohol, an amine, an amide, an ether, a polyether, a polyamide, an ester, a mercaptan, an alkylthio, a urea, a thiourea, a guanidyl, or a carbamoyl group, andType: GrantFiled: November 12, 1999Date of Patent: January 23, 2007Assignee: Invitrogen CorporationInventors: Yongliang Chu, Malek Masoud, Gulilat Gebeyehu
-
Patent number: 7129377Abstract: The present invention relates to an androgen receptor alkylating compound, wherein the compound may include, inter alia, an active functional group, which permits the alkylation of the androgen receptor.Type: GrantFiled: July 6, 2004Date of Patent: October 31, 2006Assignee: University of Tennessee Research FoundationInventors: Duane D. Miller, Leonid I. Kirkovsky, James T. Dalton, Arnab Mukherjee
-
Patent number: 7078565Abstract: Disclosed are phenyl-alkylene benzamides useful as orexin antagonistsType: GrantFiled: October 30, 2002Date of Patent: July 18, 2006Assignee: SmithKline Beecham plcInventors: Wai Ngor Chan, Amanda Johns, Roderick Alan Porter, Rachel Elizabeth Anne Stead, Mythily Vimal